Linezolid Inteli

Linezolid, the active ingredient in Linezolid Inteli, is an oxazolidinone presented as an intravenous formulation for use in adult patients. It treats skin and soft‑tissue infections and both community‑acquired and hospital‑acquired pneumonia caused by susceptible Gram‑positive bacteria, including methicillin‑resistant Staphylococcus aureus (MRSA) and vancomycin‑resistant Enterococcus (VRE). GNH USA supplies Linezolid Inteli as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. This ensures timely delivery and regulatory compliance across regions.

Linezolid is an oxazolidinone antibacterial used to treat infections caused by susceptible Gram‑positive bacteria. - Skin and soft tissue infections: effective against MRSA and other susceptible Gram‑positive organisms, leading to resolution of cellulitis, abscesses, and wound infections. - Community‑acquired pneumonia: reduces bacterial load in the lungs, improving respiratory function and shortening illness duration. - Hospital‑acquired pneumonia: targets resistant Gram‑positive pathogens, supporting recovery in critically ill patients. - Infections caused by vancomycin‑resistant Enterococcus (VRE): provides an alternative therapeutic option when other agents fail.

Linezolid may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring in some patients. - Diarrhea: loose stools that may be self‑limiting. - Headache: transient cranial discomfort. - Metallic taste: altered taste perception during therapy.

Serious or Rare Side Effects: - Thrombocytopenia: significant reduction in platelet count requiring monitoring. - Peripheral neuropathy: nerve damage presenting as tingling or numbness. - Serotonin syndrome: risk when combined with serotonergic agents, leading to agitation, hyperreflexia, and fever.

When prescribing Linezolid, clinicians should consider several safety and handling measures. - Renal impairment: adjust monitoring as accumulation may occur. - Hepatic dysfunction: evaluate liver function before and during therapy. - Hematologic monitoring: perform regular complete blood counts to detect thrombocytopenia or anemia. - Concomitant serotonergic drugs: avoid or monitor closely for serotonin syndrome. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Linezolid can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs), serotonin‑norepinephrine reuptake inhibitors (SNRIs) and monoamine oxidase inhibitors (MAOIs): may precipitate serotonin syndrome. - Rifampicin: induces hepatic enzymes, markedly reducing linezolid plasma concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR, requiring closer coagulation monitoring. - Ethanol: may enhance disulfiram‑like reactions, causing flushing and nausea. - Antacids containing aluminum or magnesium: may slightly decrease absorption, monitor therapeutic response.